Skip to main content
SpringerLink
Log in

Heart Transplantation

  • Chapter
  • First Online:
Pediatric Critical Care Medicine

  • 1936 Accesses

Abstract

Heart transplantation has long been an acceptable form of pediatric therapy for end-stage heart failure secondary to genetic or acquired cardiomyopathy. Other indications include heart failure after palliation of congenital heart disease or for congenital heart disease not amenable to standard surgical approaches. Over the decades, survival outcome after pediatric heart transplantation has improved. Optimal post-transplant outcome can be attributed to all phases of care including the identification, evaluation, and care of the pre-transplant candidate, intra-operative and immediate post-operative approaches, and long-term management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41:1271–4.

    CAS  PubMed  Google Scholar 

  2. Kantrowitz A, Haller JD, Joos H, Cerruti MM, Carstensen HE. Transplantation of the heart in an infant and an adult. Am J Cardiol. 1968;22:782–90.

    Article  CAS  PubMed  Google Scholar 

  3. Caves PK, Stinson EB, Billingham ME, Shumway NE. Transvenous intracardiac biopsy using a new catheter forceps. Heart Lung J Crit Care. 1975;4(1):69–74.

    CAS  Google Scholar 

  4. Billingham M. Diagnosis of cardiac rejection by endomyocardial biopsy. J Heart Transplant. 1982;1:25–30.

    Google Scholar 

  5. Kirk R, Dipchand AI, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric heart transplantation report–2012. J Heart Lung Transplant. 2012;31(10):1065–72.

    Article  PubMed  Google Scholar 

  6. (HRSA) Health Resources and Services Administration. (SRTR) Scientific Registry of Transplant Recipients. 2011 annual data report. http://srtr.transplant.hrsa.gov/annual_reports/2011/ (2013). Accessed 8 May 2013.

  7. Kirk R, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report–2010. J Heart Lung Transplant. 2010;29(10):1119–28.

    Article  PubMed  Google Scholar 

  8. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. 2001;138(4):505–11.

    Article  CAS  PubMed  Google Scholar 

  9. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant. 2002;21(8):906–9.

    Article  PubMed  Google Scholar 

  10. Azeka E, Franchini Ramires JA, Valler C, Alcides BE. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol. 2002;40(11):2034–8.

    Article  CAS  PubMed  Google Scholar 

  11. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant. 2004;23(7):832–8.

    Article  PubMed  Google Scholar 

  12. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298(10):1171–9.

    Article  PubMed  Google Scholar 

  13. O’Sullivan JJ, Roche SL, Crossland DS, Chaudhari MP, Kirk RC, Asif H. Recovery of heart function in children with acute severe heart failure. Transplantation. 2008;85(7):975–9.

    Article  PubMed  Google Scholar 

  14. Erdogan I, Ozer S, Karagoz T, Celiker A, Ozkutlu S, Alehan D. Treatment of dilated cardiomyopathy with carvedilol in children. Turk J Pediatr. 2009;51(4):354–60.

    PubMed  Google Scholar 

  15. Petko C, Minich LL, Everitt MD, Holubkov R, Shaddy RE, Tani LY. Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. Pediatr Cardiol. 2010;31(6):780–4.

    Article  PubMed  Google Scholar 

  16. Gajarski RJ, Towbin JA, Bricker JT, et al. Intermediate follow-up of pediatric heart transplant recipients with elevated pulmonary vascular resistance index. J Am Coll Cardiol. 1994;23(7):1682–7.

    Article  CAS  PubMed  Google Scholar 

  17. Addonizio LJ, Gersony WM, Robbins RC, et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation. 1987;76(5 Pt 2):V52–5.

    CAS  PubMed  Google Scholar 

  18. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant. 1993;12(2):179–84.

    CAS  PubMed  Google Scholar 

  19. Kieler-Jensen N, Ricksten SE, Stenqvist O, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant. 1994;13(3):366–75.

    CAS  PubMed  Google Scholar 

  20. Kimberling MT, Balzer DT, Hirsch R, Mendeloff E, Huddleston CB, Canter CE. Cardiac transplantation for pediatric restrictive cardiomyopathy: presentation, evaluation, and short-term outcome. J Heart Lung Transplant. 2002;21(4):455–9.

    Article  PubMed  Google Scholar 

  21. Weiss CI, Park JV, Bolman RM. Prostaglandin E1 for treatment of elevated pulmonary vascular resistance in patients undergoing cardiac transplantation. Transplant Proc. 1989;21(1 Pt 3):2555–6.

    CAS  PubMed  Google Scholar 

  22. Hsu RB, Lin FY, Chou NK, Ko WJ, Chi NH, Wang SS. Heart transplantation in patients with extreme right ventricular failure. Eur J Cardiothorac Surg. 2007;32(3):457–61.

    Article  PubMed  Google Scholar 

  23. Grady KL, White-Williams C, Naftel D, et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Cardiac Transplant Research Database (CTRD) Group. J Heart Lung Transplant. 1999;18(8):750–63.

    Article  CAS  PubMed  Google Scholar 

  24. Kaufman BD, Chuai S, Dobbels F, Shaddy RE. Wasting or obesity at time of transplant does not predict pediatric heart transplant outcomes: analysis of ISHLT pediatric heart transplant registry. J Heart Lung Transplant. 2009;28(12):1273–8.

    Article  PubMed  Google Scholar 

  25. (HRSA) Health Resources and Services Administration. OPTN/SRTR 2009 annual report. http://www.ustransplant.org/annual_reports/current/1103_hr.pdf (2013). Accessed 8 May 2013.

  26. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107:3124–8.

    Article  PubMed  Google Scholar 

  27. Canter CE, Moorhead S, Saffitz JE, Huddleston CB, Spray TL. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant. 1994;13(1 Pt 1):74–9; discussion 79–80.

    CAS  PubMed  Google Scholar 

  28. Chiavarelli M, Gundry SR, Razzouk AJ, Bailey LL. Cardiac transplantation for infants with hypoplastic left-heart syndrome. JAMA. 1993;270(24):2944–7.

    Article  CAS  PubMed  Google Scholar 

  29. Morrow WR, Naftel D, Chinnock R, et al. Outcome of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplantation. The Pediatric Heart Transplantation Study Group. J Heart Lung Transplant. 1997;16(12):1255–66.

    CAS  PubMed  Google Scholar 

  30. Almond CS, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation. 2009;119(5):717–27.

    Article  PubMed  Google Scholar 

  31. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.

    Article  PubMed  Google Scholar 

  32. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53.

    Article  PubMed  Google Scholar 

  33. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.

    Article  CAS  PubMed  Google Scholar 

  34. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.

    Article  CAS  PubMed  Google Scholar 

  35. Rosner MH, Rastogi A, Ronco C. The cardiorenal syndrome. Int J Nephrol. 2011;2011:982092.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Jefferies JL, Goldstein SL. Cardorenal syndrome: an emerging problem in pediatric critical care. Pediatr Nephrol. 2012;28:855–62.

    Article  PubMed  Google Scholar 

  37. Price JF, Mott AR, Dickerson HA, et al. Worsening renal function in children hospitalized with decompensated heart failure: evidence for a pediatric cardiorenal syndrome? Pediatr Crit Care Med. 2008;9(3):279–84.

    Article  PubMed  Google Scholar 

  38. Alvarez JA, Orav EJ, Wilkinson JD, et al. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. Circulation. 2011;124(7):814–23.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Jefferies JL, Morales DL. Mechanical circulatory support in children: bridge to transplant versus recovery. Curr Heart Fail Rep. 2012;9(3):236–43.

    Article  PubMed  Google Scholar 

  40. Jefferies JL, Price JF, Morales DL. Mechanical support in childhood heart failure. Heart Fail Clin. 2010;6(4):559–73, x.

    Article  PubMed  Google Scholar 

  41. Stewart GC, Givertz MM. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation. 2012;125(10):1304–15.

    Article  PubMed  Google Scholar 

  42. Rossano JW, Morales DL, Zafar F, et al. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2010;140(3):694–9, 699 e1–2.

    Article  PubMed  Google Scholar 

  43. Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac tranplantation? Circulation. 1996;94(9 suppl):II294–7.

    CAS  PubMed  Google Scholar 

  44. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26:876–82.

    Article  PubMed  Google Scholar 

  45. Lick SD, Beckles DL, Piovesana G, et al. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. Ann Thorac Surg. 2011;92(4):1428–34.

    Article  PubMed  Google Scholar 

  46. McIntyre JA, Higgins N, Britton R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation. 1996;62(5):691–3.

    Article  CAS  PubMed  Google Scholar 

  47. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation. 2012;93(3):319–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–51.

    Article  CAS  PubMed  Google Scholar 

  49. Kirk R, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric heart transplantation report-2011. J Heart Lung Transplant. 2011;30(10):1095–103.

    Article  PubMed  Google Scholar 

  50. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twelfth official pediatric heart transplantation report-2009. J Heart Lung Transplant. 2009;28(10):993–1006.

    Article  PubMed  Google Scholar 

  51. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15(5):435–42.

    CAS  PubMed  Google Scholar 

  52. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant. 1999;18:460–9.

    Article  PubMed  Google Scholar 

  53. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation. 2005;80(4):477–81.

    Article  CAS  PubMed  Google Scholar 

  54. Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation. 2003;75(3):354–8.

    Article  PubMed  Google Scholar 

  55. Parisi F, Danesi H, Squitieri C, Di Chiara L, Rava L, Di Donato RM. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant. 2003;22(5):591–3.

    Article  CAS  PubMed  Google Scholar 

  56. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110(24):3734–40.

    Article  PubMed  Google Scholar 

  57. Boucek MM, Edwards LB, Berkeley MK, Trulock EP, Taylor DO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report - 2005. J Heart Lung Transplant. 2005;24:968–82.

    Article  PubMed  Google Scholar 

  58. Haddad M, Alghofaili FS, Fergusson DA, Masters RG. Induction immunosuppression after heart transplantation: monoclonal vs. polyclonal antithymoglobulins. Is there a difference? Interact Cardiovasc Thorac Surg. 2005;4(5):415–9.

    Article  PubMed  Google Scholar 

  59. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217–24.

    CAS  PubMed  Google Scholar 

  60. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(1 Suppl):37–42.

    Article  PubMed  Google Scholar 

  61. Grundy N, Simmonds J, Dawkins H, Rees P, Aurora P, Burch M. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation. J Heart Lung Transplant. 2009;28(12):1279–84.

    Article  PubMed  Google Scholar 

  62. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10(2):382–8.

    Article  CAS  PubMed  Google Scholar 

  63. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant. 2008;27(2):242–4.

    Article  PubMed  Google Scholar 

  64. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110(17):2694–700.

    Article  CAS  PubMed  Google Scholar 

  65. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6(5 Pt 1):986–92.

    Article  CAS  PubMed  Google Scholar 

  66. Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant. 2009;28(1):58–66.

    Article  PubMed  Google Scholar 

  67. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation. 2004;78(4):591–8.

    Article  CAS  PubMed  Google Scholar 

  68. Herzberg GZ, Rossi AF, Courtney M, et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. Am J Cardiol. 1998;82(4):541–3.

    Article  CAS  PubMed  Google Scholar 

  69. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110(25):3858–65.

    Article  CAS  PubMed  Google Scholar 

  70. Dayton JD, Richmond ME, Weintraub RG, Shipp AT, Orjuela M, Addonizio LJ. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(4):420–5.

    Article  PubMed  Google Scholar 

  71. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507–15.

    Article  CAS  PubMed  Google Scholar 

  72. Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation. 2001;72(10):1662–5.

    Article  CAS  PubMed  Google Scholar 

  73. Boucek MM, Waltz DA, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report–2006. J Heart Lung Transplant. 2006;25(8):893–903.

    Article  PubMed  Google Scholar 

  74. Canter C, Naftel D, Caldwell R, et al. Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. The Pediatric Heart Transplant Study. Circulation. 1997;96(1):227–31.

    Article  CAS  PubMed  Google Scholar 

  75. Rotondo K, Naftel DC, Boucek R, et al. Allograft rejection following cardiac transplantation in infants and children: a multi-institutional study. J Heart Lung Transplant. 1996;15:S80.

    Google Scholar 

  76. Dodd DA, Brady LD, Carden KA, Frist WH, Boucek MM, Boucek Jr RJ. Pattern of echocardiographic abnormalities with acute cardiac allograft rejection in adults: correlation with endomyocardial biopsy. J Heart Lung Transplant. 1993;12(6 Pt 1):1009–17.

    CAS  PubMed  Google Scholar 

  77. Warnecke H, Muller J, Cohnert T, et al. Clinical heart transplantation without routine endomyocardial biopsy. J Heart Lung Transplant. 1992;11(6):1093–102.

    CAS  PubMed  Google Scholar 

  78. Valantine HA, Yeoh TK, Gibbons R, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant. 1991;10(5 Pt 1):757–65.

    CAS  PubMed  Google Scholar 

  79. Wisenberg G, Pflugfelder PW, Kostuk WJ, McKenzie FN, Prato FS. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. Am J Cardiol. 1987;60(1):130–6.

    Article  CAS  PubMed  Google Scholar 

  80. Ibrahim JE, Sweet SC, Flippin M, et al. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant. 2002;21(3):311–8.

    Article  PubMed  Google Scholar 

  81. Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005;79(2):641–4; discussion 645.

    Article  PubMed  Google Scholar 

  82. Shaddy RE, Hawkins JA. Immunology and failure of valved allografts in children. Ann Thorac Surg. 2002;74:1271–5.

    Article  PubMed  Google Scholar 

  83. Shaddy RE, Thompson DD, Osborne KA, Hawkins JA, Fuller TC. Persistence of human leukocyte antigen (HLA) antibodies after one year in children receiving cryopreserved valved allografts. Am J Cardiol. 1997;80:358–9.

    Article  CAS  PubMed  Google Scholar 

  84. Brand A. Immunological aspects of blood transfusions. Transpl Immunol. 2002;10:183–90.

    Article  CAS  PubMed  Google Scholar 

  85. Lietz K, John R, Kocher A, et al. Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients. Circulation. 2001;104 suppl 1:I177–83.

    CAS  PubMed  Google Scholar 

  86. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120–5.

    Article  CAS  PubMed  Google Scholar 

  87. McKenna Jr DH, Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist support. J Heart Lung Transplant. 2002;21:1218–24.

    Article  PubMed  Google Scholar 

  88. Mehra MJ, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol. 2003;18:153–8.

    Article  PubMed  Google Scholar 

  89. Aranda Jr JM, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73(6):907–10.

    Article  PubMed  Google Scholar 

  90. Bierl C, Miller B, Prak EL, et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl. 2006;489–96.

    Google Scholar 

  91. Keren A, Hayes HM, O’Driscoll G. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. Transplant Proc. 2006;38(5):1520–2.

    Article  CAS  PubMed  Google Scholar 

  92. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant. 2010;10(9):2033–42.

    Article  CAS  PubMed  Google Scholar 

  93. Hickstein H, Korten G, Bast R, Barz D, Nizze H, Schmidt R. Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery. Clin Transplant. 2002;16(2):97–101.

    Article  CAS  PubMed  Google Scholar 

  94. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation. 2007;84(7):876–84.

    Article  PubMed  CAS  Google Scholar 

  95. Esnault V, Bignon JD, Testa A, Preud’homme JL, Vergracht A, Soulillou JP. Effect of protein A immunoadsorption on panel lymphocyte reactivity in hyperimmunized patients awaiting a kidney graft. Transplantation. 1990;50(3):449–53.

    Article  CAS  PubMed  Google Scholar 

  96. Hiesse C, Kriaa F, Rousseau P, et al. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant. 1992;7(9):944–51.

    CAS  PubMed  Google Scholar 

  97. Jin Q, Liu H, Song LY, et al. Protein A immunoadsorption therapy in the highly sensitized kidney transplant candidates. Chin Med J (Engl). 2011;124(5):780–2.

    Google Scholar 

  98. Kupin WL, Venkat KK, Hayashi H, Mozes MF, Oh HK, Watt R. Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation. 1991;51(2):324–9.

    Article  CAS  PubMed  Google Scholar 

  99. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet. 1989;1(8628):10–2.

    Article  CAS  PubMed  Google Scholar 

  100. Reisaeter AV, Leivestad T, Albrechtsen D, et al. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation. 1995;60(3):242–8.

    Article  CAS  PubMed  Google Scholar 

  101. Ross CN, Gaskin G, Gregor-Macgregor S, et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation. 1993;55(4):785–9.

    Article  CAS  PubMed  Google Scholar 

  102. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant. 2001;1(3):260–9.

    Article  CAS  PubMed  Google Scholar 

  103. Yin H, Hu XP, Li XB, et al. Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J (Engl). 2009;122(22):2752–6.

    CAS  Google Scholar 

  104. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57(4):553–62.

    Article  CAS  PubMed  Google Scholar 

  105. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(19 Suppl):II229–35.

    CAS  PubMed  Google Scholar 

  106. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–20.

    Article  PubMed  Google Scholar 

  107. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252–69.

    Article  PubMed  Google Scholar 

  108. Pahl E, Crawford SE, Cohn RA, et al. Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. Am J Cardiol. 2000;85(6):735–9.

    Article  CAS  PubMed  Google Scholar 

  109. Berglin E, Kjellstrom C, Mantovani V, Stelin G, Svalander C, Wiklund L. Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Transpl Int. 1995;8(5):382–7.

    Article  CAS  PubMed  Google Scholar 

  110. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20(3):316–21.

    Article  CAS  PubMed  Google Scholar 

  111. Baran DA, Lubitz S, Alvi S, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc. 2004;36(10):3164–6.

    Article  CAS  PubMed  Google Scholar 

  112. Garrett Jr HE, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1337–42.

    Article  PubMed  Google Scholar 

  113. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(2):158–63.

    Article  PubMed  Google Scholar 

  114. Pollock-BarZiv SM, den Hollander N, Ngan B-Y, Kantor P, McCrindle B, Dipchand AI. Pediatric heart transplantation in human leukocyte antigen-sensitized patients. Circulation. 2007;116:I-172–8.

    Article  Google Scholar 

  115. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant. 2008;12(4):442–6.

    Article  CAS  PubMed  Google Scholar 

  116. Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005;24:645–51.

    Article  PubMed  Google Scholar 

  117. Dent CL, Canter CE, Hirsch R, Balzer DT. Transplant coronary artery disease in pediatric heart transplant recipients. J Heart Lung Transplant. 2000;19:240–8.

    Article  CAS  PubMed  Google Scholar 

  118. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients. J Am Coll Cardiol. 2005;45:1532–7.

    Article  PubMed  Google Scholar 

  119. Moulik M, Breinholt JP, Dreyer WJ, et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol. 2010;56(7):582–92.

    Article  PubMed Central  PubMed  Google Scholar 

  120. Breinholt JP, Moulik M, Dreyer WJ, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant. 2010;29(7):739–46.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Heart Transplant Services, The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Clifford Chin MD

  2. Division of Cardiology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 2003, Cincinnati, OH, 45229, USA

    John Lynn Jefferies MD, MPH

Authors
  1. Clifford Chin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Lynn Jefferies MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Lynn Jefferies MD, MPH .

Editor information

Editors and Affiliations

  1. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Derek S. Wheeler

  2. Div. of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Hector R. Wong

  3. University of Michigan Medical School, Ann Arbor, Michigan, USA

    Thomas P. Shanley

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Chin, C., Jefferies, J.L. (2014). Heart Transplantation. In: Wheeler, D., Wong, H., Shanley, T. (eds) Pediatric Critical Care Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-6359-6_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6359-6_27

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6358-9

  • Online ISBN: 978-1-4471-6359-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation